Cargando…

(18)F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI

OBJECTIVE: To compare the presence of post-operative residual disease by magnetic resonance imaging (MRI) and [18F]fluorothymidine (FLT)-positron emission tomography (PET)-computer tomography (CT) in patients with malignant glioma and to estimate the impact of (18)F-FLT PET on the delineation of pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Fen, Li, Minghuan, Wang, Zhiheng, Fu, Zheng, Cui, Yunfeng, Chen, Zhaoqiu, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349865/
https://www.ncbi.nlm.nih.gov/pubmed/25738617
http://dx.doi.org/10.1371/journal.pone.0118769
_version_ 1782360097695989760
author Zhao, Fen
Li, Minghuan
Wang, Zhiheng
Fu, Zheng
Cui, Yunfeng
Chen, Zhaoqiu
Yu, Jinming
author_facet Zhao, Fen
Li, Minghuan
Wang, Zhiheng
Fu, Zheng
Cui, Yunfeng
Chen, Zhaoqiu
Yu, Jinming
author_sort Zhao, Fen
collection PubMed
description OBJECTIVE: To compare the presence of post-operative residual disease by magnetic resonance imaging (MRI) and [18F]fluorothymidine (FLT)-positron emission tomography (PET)-computer tomography (CT) in patients with malignant glioma and to estimate the impact of (18)F-FLT PET on the delineation of post-operative target volumes for radiotherapy (RT) planning. METHODS: Nineteen patients with post-operative residual malignant gliomas were enrolled in this study. For each patient, (18)F- FLT PET-CT and MRI were acquired in the same week, within 4 weeks after surgery but before the initiation of RT. The PET-CT and MRI data were co-registered based on mutual information. The residual tumor volume defined on the (18)F-FLT PET (Vol-PET) was compared with that of gadolinium [Gd] enhancement on T1-weighted MRI (Vol-T1) and areas of hyperintensity on T2-weighted MRI (Vol-T2). RESULTS: The mean Vol-PET (14.61 cm(3)) and Vol-T1 (13.60 cm(3)) were comparable and smaller than the mean Vol-T2 (32.93 cm(3)). The regions of (18)F-FLT uptake exceeded the contrast enhancement and the hyperintense area on the MRI in 14 (73.68%) and 8 patients (42.11%), respectively. In 5 (26.32%) of the 19 patients, Vol-PET extended beyond 25 mm from the margin of Vol-T1; in 2 (10.53%) patients, Vol-PET extended 20 mm from the margin of Vol-T2. Vol-PET was detected up to 35 mm away from the edge of Vol-T1 and 24 mm away from the edge of Vol-T2. In 16 (84.21%) of the 19 patients, the Vol-T1 extended beyond the Vol-PET. In all of the patients, at least some of the Vol-T2 was located outside of the Vol-PET. CONCLUSIONS: The volumes of post-operative residual tumor in patients with malignant glioma defined by (18)F-FLT uptake on PET are not always consistent with the abnormalities shown on post-operative MRI. Incorporation of (18)F-FLT-PET in tumor delineation may have the potential to improve the definition of target volume in post-operative radiotherapy.
format Online
Article
Text
id pubmed-4349865
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-43498652015-03-17 (18)F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI Zhao, Fen Li, Minghuan Wang, Zhiheng Fu, Zheng Cui, Yunfeng Chen, Zhaoqiu Yu, Jinming PLoS One Research Article OBJECTIVE: To compare the presence of post-operative residual disease by magnetic resonance imaging (MRI) and [18F]fluorothymidine (FLT)-positron emission tomography (PET)-computer tomography (CT) in patients with malignant glioma and to estimate the impact of (18)F-FLT PET on the delineation of post-operative target volumes for radiotherapy (RT) planning. METHODS: Nineteen patients with post-operative residual malignant gliomas were enrolled in this study. For each patient, (18)F- FLT PET-CT and MRI were acquired in the same week, within 4 weeks after surgery but before the initiation of RT. The PET-CT and MRI data were co-registered based on mutual information. The residual tumor volume defined on the (18)F-FLT PET (Vol-PET) was compared with that of gadolinium [Gd] enhancement on T1-weighted MRI (Vol-T1) and areas of hyperintensity on T2-weighted MRI (Vol-T2). RESULTS: The mean Vol-PET (14.61 cm(3)) and Vol-T1 (13.60 cm(3)) were comparable and smaller than the mean Vol-T2 (32.93 cm(3)). The regions of (18)F-FLT uptake exceeded the contrast enhancement and the hyperintense area on the MRI in 14 (73.68%) and 8 patients (42.11%), respectively. In 5 (26.32%) of the 19 patients, Vol-PET extended beyond 25 mm from the margin of Vol-T1; in 2 (10.53%) patients, Vol-PET extended 20 mm from the margin of Vol-T2. Vol-PET was detected up to 35 mm away from the edge of Vol-T1 and 24 mm away from the edge of Vol-T2. In 16 (84.21%) of the 19 patients, the Vol-T1 extended beyond the Vol-PET. In all of the patients, at least some of the Vol-T2 was located outside of the Vol-PET. CONCLUSIONS: The volumes of post-operative residual tumor in patients with malignant glioma defined by (18)F-FLT uptake on PET are not always consistent with the abnormalities shown on post-operative MRI. Incorporation of (18)F-FLT-PET in tumor delineation may have the potential to improve the definition of target volume in post-operative radiotherapy. Public Library of Science 2015-03-04 /pmc/articles/PMC4349865/ /pubmed/25738617 http://dx.doi.org/10.1371/journal.pone.0118769 Text en © 2015 Zhao et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Zhao, Fen
Li, Minghuan
Wang, Zhiheng
Fu, Zheng
Cui, Yunfeng
Chen, Zhaoqiu
Yu, Jinming
(18)F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI
title (18)F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI
title_full (18)F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI
title_fullStr (18)F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI
title_full_unstemmed (18)F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI
title_short (18)F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI
title_sort (18)f-fluorothymidine pet-ct for resected malignant gliomas before radiotherapy: tumor extent according to proliferative activity compared with mri
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349865/
https://www.ncbi.nlm.nih.gov/pubmed/25738617
http://dx.doi.org/10.1371/journal.pone.0118769
work_keys_str_mv AT zhaofen 18ffluorothymidinepetctforresectedmalignantgliomasbeforeradiotherapytumorextentaccordingtoproliferativeactivitycomparedwithmri
AT liminghuan 18ffluorothymidinepetctforresectedmalignantgliomasbeforeradiotherapytumorextentaccordingtoproliferativeactivitycomparedwithmri
AT wangzhiheng 18ffluorothymidinepetctforresectedmalignantgliomasbeforeradiotherapytumorextentaccordingtoproliferativeactivitycomparedwithmri
AT fuzheng 18ffluorothymidinepetctforresectedmalignantgliomasbeforeradiotherapytumorextentaccordingtoproliferativeactivitycomparedwithmri
AT cuiyunfeng 18ffluorothymidinepetctforresectedmalignantgliomasbeforeradiotherapytumorextentaccordingtoproliferativeactivitycomparedwithmri
AT chenzhaoqiu 18ffluorothymidinepetctforresectedmalignantgliomasbeforeradiotherapytumorextentaccordingtoproliferativeactivitycomparedwithmri
AT yujinming 18ffluorothymidinepetctforresectedmalignantgliomasbeforeradiotherapytumorextentaccordingtoproliferativeactivitycomparedwithmri